NP-137 is under clinical development by Netris Pharma and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect NP-137’s likelihood of approval (LoA) and phase transition for Uterine Cancer took place on 26 Jul 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their NP-137 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
NP-137 is under development for the treatment of advanced pancreatic ductal adenocarcinoma, uterine cancer, endometrial carcinoma, cervix carcinoma, colon carcinoma, hepatocellular carcinoma and solid tumors including Head and Neck, Melanoma, Non-Small Cell Lung Cancer, Urothelial and other tumor types.. It is administered as an infusion through intravenous route. The drug candidate is a humanized monoclonal IgG1 antibody, which acts by targeting netrin-1 ligand. It was also under development for the treatment of hematologic malignancies.
Netris Pharma overview
Netris Pharma is a clinical-stage biopharmaceutical company that develops anti-cancer therapeutic molecules, principally monoclonal antibodies. Its novel drugs based on dependence receptor biology blocks the interaction among dependence receptors and their ligands. The company’s pipeline products include NP137, NP137+ pembro and carbotaxol, NP137+ approved immune checkpoint, NP137 + atezo-bev, NP137+ folferinox, NP137P, NP137R, NP701, NP100. Its pipeline portfolio includes drugs for the treatment of various cancers such as all advanced tumors, endometrium and cervix, head and neck, colon, urothelial, liver, pancreas, non-cancer indication, netrin-1 expressing cancer, hedgehog expressing cancer and glioblastoma. The company collaborates with academic institutions, research, clinical and corporate partners which include Leon Berard, Hospices Civils De Lyon, Grenoble Alpes, Arcagy Gineco, Bpifrance, La Region Auvergne-Rhone-Alpes, Lyonbiopole, Claude Bernard University Lyon, University of Lyon, Inserm Transfert and Centre National De La Recherche Scientifique (CNRS), among others. Netris is the first spin-off of Centre Leon Berard and the Cancer Research Center of Lyon. Netris Pharma is headquartered in Lyon, Rhone Alpes, France.
Quick View NP-137 LOA Data
|Highest Development Stage|